Pdl Biopharma, Inc. Watch

from 10-K 1 page Schedule of Amendment to Omitted Credit Agreements

from 10-Q 1 page Schedule of Amendment to Omitted Credit Agreement

from 10-K ~5 pages Schedule of Amendment to Omitted Credit Agreements

from 10-K/A 8 pages Second Amendment to Amended and Restated Credit Agreement

from 8-K 215 pages Credit Agreement Dated as of March 30, 2015, Among PDL Biopharma, Inc., as Borrower, the Lenders Party Hereto and Royal Bank of Canada, as Administrative Agent Rbc Capital Markets* and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Bookrunners

from 10-K 1 page Schedule of Amendment to Omitted Credit Agreement

from 10-K 9 pages Third Amendment to Amended and Restated Credit Agreement

from 10-K 8 pages Second Amendment to Amended and Restated Credit Agreement

from 10-Q 13 pages Whereas, the Borrower, the Lenders Party Thereto and the Administrative Agent and the Other Parties Named Therein, Are Party to That Certain Credit Agreement, Dated as of October 28, 2013 (As Amended, Amended and Restated, Supplemented or Otherwise Modified to (But Not Including) the Date Hereof, the “Credit Agreement”) Pursuant to Which the Lenders Have Made Certain Extensions of Credit Available to and on Behalf of the Borrower; and Whereas, the Borrower and the Required Lenders Party Hereto Have Agreed to Amend the Credit Agreement, but Only on the Terms and Conditions Herein Set Forth. Now, Therefore, in Consideration of the Premises and Covenants Contained Herein and for Other Good and Valuable Consideration, the Receipt and Sufficiency of Which Are Hereby Acknowledged, the Parties Hereto, Intending to Be Legally Bound Hereby, Agree as Follows: Section 1.credit Agreement Amendments

from 10-Q 14 pages First Amendment to Amended and Restated Credit Agreement

from 8-K 6 pages Whereas, the Borrower, the Lenders Party Thereto and the Administrative Agent and the Other Parties Named Therein, Are Party to That Certain Credit Agreement, Dated as of October 28, 2013, as Amended by Amendment No. 1 to the Credit Agreement, Dated as of February 5, 2014 (As in Effect Immediately Prior to This Amendment, the “Credit Agreement”) Pursuant to Which the Lenders Have Made Certain Extensions of Credit Available to and on Behalf of the Borrower; and Whereas, the Borrower and the Lenders Party Hereto Have Agreed to Clarify Certain Provisions of the Credit Agreement as Herein Set Forth, but Only on the Terms and Conditions Herein Set Forth. Now, Therefore, in Consideration of the Premises and Covenants Contained Herein and for Other Good and Valuable Consideration, the Receipt and Sufficiency of Which Are Hereby Acknowledged, the Parties Hereto, Intending to Be Legally Bound Hereby, Agree as Follows: Section 1. Amendments to Credit Agreement. 1.1 Amendment to Section 6.10. Section 6.10 of the Credit Agreement Is Amended and Restated in Its Entirety as Follows: Debt Service Coverage Ratio. the Borrower Will Not Permit the Debt Service Coverage Ratio, in Each Case as of the Last Day of Each Test Period, to Be Less Than 1.25 to 1.00. 1.2 Amendment to Section 6.11. Section 6.11 of the Credit Agreement Is Amended and Restated in Its Entirety as Follows: Total Leverage Ratio. the Borrower Will Not Permit the Total Leverage Ratio, as of the Last Day of Each Test Period, to Exceed 2.00 to 1.00

from 10-Q 1 page Schedule of Omitted Credit Agreement

from 10-K 62 pages Form of Credit Agreement

from 10-Q 72 pages Amended and Restated Credit Agreement Dated as of August 15, 2013 Among Wellstat Diagnostics, LLC as the Borrower, Pdl Biopharma, Inc., as the Lender, and Pdl Biopharma, Inc., as the Agent

from 8-K 219 pages Credit Agreement Dated as of October 28, 2013, Among Pdl Biopharma, Inc., as Borrower, the Lenders Party Hereto and Royal Bank of Canada, as Administrative Agent Rbc Capital Markets* and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Bookrunners

from 10-K/A 72 pages Credit Agreement Dated as of November 2, 2012 Among Wellstat Diagnostics, LLC as the Borrower, PDL Biopharma, Inc., as the Lender, and PDL Biopharma, Inc., as the Agent

from 10-Q 66 pages Credit Agreement Dated as of April 18, 2013 Among Avinger, Inc. as the Borrower, Pdl Biopharma, Inc., as the Lender, and Pdl Biopharma, Inc., as the Agent 1

from 10-Q/A 111 pages Credit Agreement Dated as of July 10, 2012 Among Merus Labs International Inc., as Borrower, Merus Labs Luxco S.À R.L, Merus Labs Inc., Ecg Holdings Inc., and Merus Labs Netherlands B.V. as Loan Parties, PDL Biopharma, Inc., as Lender, and PDL Biopharma, Inc., as Agent

from 10-K 67 pages Credit Agreement Dated as of November 2, 2012 Among Wellstat Diagnostics, LLC as the Borrower, Pdl Biopharma, Inc., as the Lender, and Pdl Biopharma, Inc., as the Agent

from 10-Q 70 pages Credit Agreement Dated as of July 10, 2012 Among Merus Labs International Inc., as Borrower, Merus Labs Luxco S.À R.L, Merus Labs Inc., Ecg Holdings Inc., and Merus Labs Netherlands B.V. as Loan Parties, Pdl Biopharma, Inc., as Lender, and Pdl Biopharma, Inc., as Agent